Abstract
Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m2 and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.
Original language | English (US) |
---|---|
Pages (from-to) | 182-188 |
Number of pages | 7 |
Journal | Cancer Investigation |
Volume | 25 |
Issue number | 3 |
DOIs | |
State | Published - Apr 2007 |
Keywords
- Carboplatin
- Chemotherapy
- Docetaxel
- Head and neck cancer
- Taxane
ASJC Scopus subject areas
- Cancer Research
- Oncology